Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 94,407,744
  • Shares Outstanding, K 1,672,710
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.00
  • Price/Sales 4.80
  • Price/Cash Flow 18.16
  • Price/Book 5.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.01 +22.67%
on 01/26/17
57.21 -1.35%
on 02/21/17
+7.48 (+15.28%)
since 01/24/17
3-Month
46.01 +22.67%
on 01/26/17
60.45 -6.63%
on 01/10/17
-0.31 (-0.55%)
since 11/23/16
52-Week
46.01 +22.67%
on 01/26/17
77.12 -26.82%
on 07/15/16
-5.79 (-9.30%)
since 02/24/16

Most Recent Stories

More News
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

I.TO : 3.40 (+21.00%)
BMY : 56.44 (+1.20%)
IPCI : 2.55 (+18.60%)
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

AZN : 29.35 (-0.54%)
MRK : 66.16 (+0.47%)
LLY : 82.87 (+0.39%)
NVS : 77.28 (-0.22%)
PFE : 34.26 (+0.59%)
GSK : 41.56 (+0.17%)
BMY : 56.44 (+1.20%)
Company News for February 23, 2017

Companies In The News are: TOL,FSLR,GRMN,BMY

TOL : 33.74 (-0.65%)
FSLR : 37.90 (+1.91%)
GRMN : 53.03 (+1.38%)
BMY : 56.44 (+1.20%)
Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has agreed to sell $1.5 billion of senior unsecured notes: $750 million in aggregate principal amount of 1.600% notes...

MS : 45.53 (-2.25%)
BMY : 56.44 (+1.20%)
Bristol Myers' Future Unsure as Carl Icahn Takes Stake

Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?

MRK : 66.16 (+0.47%)
BMY : 56.44 (+1.20%)
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

EXAS : 21.42 (-1.20%)
EXEL : 21.69 (-0.23%)
PCRX : 43.45 (-1.03%)
BMY : 56.44 (+1.20%)
Can Carl Icahn Save Bristol Myers Squibb?

Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

MRK : 66.16 (+0.47%)
BMY : 56.44 (+1.20%)
Bristol-Myers Squibb Appoints Three New Independent Directors

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its Board of Directors, effective...

BMY : 56.44 (+1.20%)
First Comprehensive Pediatric Hematology-Oncology Initiative Launched in Africa

--The $100 million initiative to create a pediatric hematology-oncology treatment network and care infrastructure is supported by $50 million donation from the Bristol-Myers Squibb Foundation and matched...

BMY : 56.44 (+1.20%)
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

AZN : 29.35 (-0.54%)
JNJ : 122.73 (+0.85%)
MRK : 66.16 (+0.47%)
LLY : 82.87 (+0.39%)
AGN : 245.37 (-0.67%)
VRX : 16.18 (-2.41%)
BMY : 56.44 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 56.85
1st Resistance Point 56.65
Last Price 56.44
1st Support Level 56.06
2nd Support Level 55.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.